Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy

Journal of Clinical Virology

Volumn 39, Issue 1, 2007, Pages 48-50

  Schnepf, Nathalie ^a   Sellier, Pierre ^a   Bendenoun, Marc ^a   Zini, Jean Marc ^a   Sanson le pors, Marie José ^a   Mazeron, Marie Christine ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Adefovir; Lamivudine; Occult hepatitis B; Reactivation; Resistance

Indexed keywords

ADEFOVIR; CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; LAMIVUDINE; PREDNISONE; STEROID; VINCRISTINE; ZIDOVUDINE;

ADD ON THERAPY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS STRAIN;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; LYMPHOMA, NON-HODGKIN; MALE; VIRUS ACTIVATION;

EID: 34247142265     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2007.01.011     Document Type: Article

References (14)

1. Behler C.M., and Kaplan L.D. Advances in the management of HIV-related non-Hodgkin lymphoma. Curr Opin Oncol 18 (2006) 437-443
2. Chemin I., Zoulim F., Merle P., Arkhis A., Chevallier M., Kay A., Civa L., Chevallier P., Mandrand B., and Trépo C. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 34 (2001) 447-454
3. Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis. Cancer Invest 24 (2006) 548-552
4. EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol 38 (2003) 533-540
5. Filippini P., Coppola N., Pisapia R., Scolastico C., Marrocco C., Zaccariello A., Nacca C., Sagnelli C., De Stefano G., Ferraro T., De Stephano C., and Sagnelli E. Impact of occult hepatitis B virus infection in HIV patients naïve for antiretroviral therapy. AIDS 12 (2006) 1253-1260
6. Kohrt H.E., Ouyang D.L., and Keeffe E.B. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmocol Ther 24 (2006) 1003-1016
7. Law J.K., Ho J.K., Hoskins P.J., Erb S.R., Steinbrecher U.P., and Yoshida E.M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46 (2005) 1085-1089
8. Lee C.H., Kim S.-O., Byun K.S., Moon M.S., Kim E.-O., Yeon J.E., Yoo W., and Hong S.P. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterol 130 (2006) 1144-1152
9. Li Y.-H., He Y.-F., Jiang W.-Q., Wang F.-H., Lin X.-B., Zhang L., Xia Z.-J., Sun X.-F., Huang H.-Q., Lin T.-Y., He Y.-J., and Guan Z.-Z. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who received chemotherapy for lymphoma. Cancer 106 (2006) 1320-1325
10. Lok A.S.F., and McMahon B.J. Chronic hepatitis B: update of recommendations. Hepatology 39 (2004) 857-861
11. Neau D., Winnock M., Jouvencel A.-C., Faure M., Castéra L., Legrand E., Lacoste D., Ragnaud J.-M., Dupon M., Fleury H., Lafon M.-E., and Dabis F. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine Cohort 2002-2003. Clin Infect Dis 40 (2005) 750-753
12. Puoti M., Spinetti A., Ghezzi A., Donato F., Zaltron S., Putzolu V., Quiros-Roldan E., Zanini B., Casari S., and Carosi G. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 24 (2000) 211-217
13. Shire N.J., Rouster S.D., Rajicic N., and Shermann K.E. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 36 (2004) 869-875
14. Simpson N., Simpson P.W., Ahmed A.M., Nguyen M.H., Garcia G., Keeffe E.B., and Ahmed A. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol 37 (2003) 68-71